Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Levodopa-Carbidopa · 1 trial · 1 indication
Levodopa, Carbidopa and Metabolite:Cmax, Cmin, Area Under Curve, T max, half life, peak-trough fluctuation.
Evaluation of orthostatic vitals signs, ECGs, and adverse event monitoring (Screening, Day -1, Day 1, Day 2), clinical lab testing and physical exam (Screening and Day 2)
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Levodopa-Carbidopa | DRUG | Intestinal Gel |
Inclusion Criteria 1. Male or female subjects at least 30 years old; 2. Subjects with advanced Parkinson's disease who are already on LCIG (Duodopa®) for at least 30 days; 3. Body mass index range from 18.0 to 30.0 kg/m2 Exclusion Criteria 1. Subjects who are considered to be violent or subjects ...
Levodopa-Carbidopa is an investigational small molecule being studied for the treatment of Parkinson Disease. It is formulated as an intestinal gel and is intended for patients with advanced Parkinson's Disease. The drug is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
Levodopa-Carbidopa is being developed by AbbVie Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol ABBV. The company is conducting clinical research on this drug for the treatment of Parkinson Disease.
Levodopa-Carbidopa is in Phase 1 clinical development. It is an investigational drug and has not been approved for commercial use. The Phase 1 trial has been completed, and the drug remains in early-stage clinical testing for Parkinson Disease.
Levodopa-Carbidopa has one completed clinical trial registered under NCT01484990, titled "A Pharmacokinetic Study of Levodopa and Carbidopa Intestinal Gel in Subjects With Advanced Parkinson's Disease." This Phase 1 study enrolled 19 participants and was uncontrolled, meaning it did not use a comparison group.
Levodopa-Carbidopa is a combination of the two active ingredients levodopa and carbidopa. The drug is being studied as an intestinal gel formulation for advanced Parkinson's Disease. It is currently in Phase 1 clinical development and is not yet approved.